FDA Approved: SAVAYSA — Supplemental Application (Daiichi Sankyo Inc.)

View source ↗

Summary

FDA approved a supplemental application for SAVAYSA (edoxaban tosylate) submitted by Daiichi Sankyo Inc., likely updating labeling and/or indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonvalvular Atrial Fibrillation
• Venous Thromboembolism

Drugs mentioned

• Savaysa (edoxaban)

Snippet

SUPPL AP for SAVAYSA (EDOXABAN TOSYLATE)